

Request under Freedom of Information Act 2000

**Request Ref: NGFOI 19/20: 086**

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 16/05/2019.

**I am pleased to be able to provide you with the following information:**

1. *In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?*

**337**

2. *Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS;*

>RMS  
 >PPMS  
**>Not known**

3. *How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months. Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:*

<i>Aubagio (teriflunomide)</i>	<b>34</b>
<i>Avonex (interferon beta-1a)</i>	<b>8</b>
<i>Betaferon (interferon beta-1b)</i>	<b>0</b>
<i>Brabio (glatiramer acetate)</i>	<b>0</b>
<i>Copaxone (glatiramer acetate)</i>	<b>33</b>
<i>Extavia (beta interferon-1b)</i>	<b>*</b>
<i>Gilenya (fingolimod)</i>	<b>12</b>
<i>Lemtrada (alemtuzumab)</i>	<b>9</b>
<i>Mavenclad (cladribine)</i>	<b>0</b>
<i>Ocrevus (Ocrelizumab)</i>	<b>0</b>
<i>Plegridy (Peginterferon beta-1a)</i>	<b>9</b>
<i>Rebif (beta interferon-1a)</i>	<b>27</b>
<i>Tecfidera (dimethyl fumarate)</i>	<b>48</b>
<i>Tysabri (natalizumab)</i>	<b>18</b>
<i>Zinbryta (daclizumab)</i>	<b>0</b>
<i>Ampyra (Fampyra)</i>	<b>0</b>

**\* Due to the low numbers involved the exact figures have been withheld under the Freedom of Information Act, Exemption Section 40. This is to protect the identity of the individuals concerned and to preserve their rights under the Data Protection Act.**